series-c
Stage
2017
Founded
2
Investors
About
Fore Biotherapeutics is a virtual biotechnology company developing plixorafenib, a next-generation BRAF inhibitor in global Phase 2 trials intended to treat advanced solid tumors with BRAF alterations.
Explore Fore Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.